Biopharmaceutical manufacturers are facing increasing pressures to improve productivity and reduce time to clinic and market. Increasing productivity begins with selecting the appropriate expression system for each protein. Current efforts to boost expression titers also are focused on implementing selection/screening technologies, engineering Chinese hamster ovary (CHO) expression systems, and accelerating timelines for the development of complex next-generation therapies. BioProcess International asked three representatives of the industry’s leading companies to comment on current expression system technologies and strategies Just fill out this…
Tuesday, May 28, 2019 Daily Archives
Novartis to end $300m a year facility services deal with ISS
Eight years after inking a deal to provide facilities services across 22 sites, Danish firm ISS says Novartis is unlikely to extend its contract beyond December. In August 2012, Swiss pharma firm Novartis inked a deal with Danish facilities services provider ISS to provide integrated facilities services at 22 sites, including numerous production plants. The deal included the fulfilment of services including catering, property, cleaning, support and security at five sites in Switzerland, eleven sites in Germany, two in Austria,…
Will GSK have the capacity to bring Shingrix to China?
GlaxoSmithKline (GSK) has received Chinese approval for its shingles vaccine Shingrix, but with demand already outstripping supply the firm must invest significantly in its production capabilities. China’s National Medical Products Administration (NMPA) has approved Shingrix, a non-live, recombinant subunit vaccine for the prevention of shingles (herpes zoster) in adults aged over 50. Shingrix underwent an expedited review after falling on a list of 48 ‘clinically urgently needed new medicines’ in China aimed at bringing critical new prevention and treatment options…